Article
Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
Genome medicine - 30 Dec 2019
van den Bulk Jitske, Verdegaal Els M E, Ruano Dina, Ijsselsteijn Marieke E, Visser Marten, van der Breggen Ruud, Duhen Thomas, van der Ploeg Manon, de Vries Natasja L, Oosting Jan, Peeters Koen C M J, Weinberg Andrew D, Farina-Sarasqueta Arantza, van der Burg Sjoerd H, de Miranda Noel F C C
Abstract excerpt
BACKGROUND: The efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch repair-deficient tumors having high mutation burden. However, this observation does not exclude the existence of neoantigen-specific T cells in colorectal cancers with low mutation burden and the exploitation of their anti-cancer potential for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.